Rongcan Bio, founded in 2020, is a pioneering company operating within the Biopharma, Biotechnology, and Pharmaceutical sectors. The company aims to revolutionize the nucleic acid industry by offering a broad range of services from nucleic acid sequence design to final drug delivery. This positions Rongcan Bio as a fully integrated service provider, streamlining the development and industrialization of nucleic acid drugs.
Embodying its slogan, "Completing the entire nucleic acid industry cycle, from sequence design to drug delivery," the company has successfully secured a CNY100.00M Series A investment as of 06 December 2023. This substantial investment round featured prominent investors, including Shaanxi Investment Capital, Beijing Huafang Investment, Zhangjiagang Jintai Jinhong Investment Management, and Guangzhou Yuexiu Industrial Investment Fund, showcasing strong investor confidence in its comprehensive approach to nucleic acid drug development.
